FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup
Published: May 18, 2020
Abstract
Atezolizumab was approved as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA approved test, with no EGFR or ALK genomic tumor...
Paper Details
Title
FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup
Published Date
May 18, 2020
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History